Rivaroxaban

Details

Generic Name:
Rivaroxaban (granules for oral suspension)
Project Status:
Not filed
Therapeutic Area:
Venous Thromboembolic Events
Manufacturer:
Bayer Inc
Brand Name:
Xarelto
Project Line:
Reimbursement Review
Project Number:
N/A
Submission Type:
Non Submission
Indications:
The treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer